Citius Pharmaceuticals is trading at $0.53, down 7.74%, with no fresh company-specific announcement identified to explain the decline. - On September 28, global stocks fell as renewed U.S.-Iran tensions lifted oil prices and rising Treasury yields reinforced inflation and higher-for-longer interest-rate concerns. - The latest listed investor-conference news dates to September 3. Major U.S. indices were also lower, making broader risk-off trading a plausible context, though no source directly linked it to the stock’s drop.